Filter
430
Text search:
PrEP
Featured
60
102
Language
Document type
180
96
73
23
20
14
8
7
4
2
1
Countries / Regions
18
17
13
12
9
6
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
133
34
21
7
7
4
1
Toolboxes
183
19
13
11
10
9
7
7
7
7
5
4
3
3
2
2
2
2
2
1
1
1
Accessed: 29.02.2020
Adolescent girls and young women (AGYW) remain disproportionately affected by HIV in Eastern and Southern Africa (ESA), with 26 per cent of new infections attributed to this population. AGYW face many personal, social and structural barriers to access, uptake and use of traditional HIV prevention me
...
Impact of PEPFAR Stop Work Orders on PrEP
recommended
The widespread termination of US government contracts and PEPFAR stop work orders have had a devastating impact on access to HIV prevention. To find out more about what happened and understand the ongoing impacts in detail, click on the link
Factsheet
Download Kiswahili or English frequently asked questions about PrEP.
Evidence shows that oral pre-exposure prophylaxis (PrEP) reduces the risk of contracting HIV during sexual intercourse by more than 90% when taken daily. It is for this reason the National HIV Prevention Strategy 2015-2020 (2018 Revision) emphasi
...
Technical Brief
July 2017
Herramienta de estimación de necesidades y costos de la profilaxis preexposición (PrEP). Instruccciones de uso. En particular, calcula 1) el número de personas que se beneficiarían de la PrEP, e
...
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex F
what lessons can we take from the last few decades of health behaviour change efforts as we enter the era of HIV prevention pills, rings and injections?
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex C
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex D
This brief from Audere and AVAC explains how artificial intelligence (AI) can support the HIV field by expanding reach, enhancing prevention, and improving care.
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely
...
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that
...
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP
...
